Published in Eur Heart J on July 01, 1998
Incidence and epidemiology of heart failure. Heart Fail Rev (2000) 2.91
Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail (2009) 2.51
Death in heart failure: a community perspective. Circ Heart Fail (2008) 2.46
The evidence for beta blockers in heart failure. BMJ (1999) 1.84
Can heart failure be diagnosed in primary care? BMJ (2000) 1.61
Non-cardiac comorbidities in chronic heart failure. Heart (2006) 1.19
Heart failure and cognitive impairment: challenges and opportunities. Clin Interv Aging (2007) 1.18
Management of heart failure: evidence versus practice. Does current prescribing provide optimal treatment for heart failure patients? Br J Gen Pract (2000) 1.01
Patients with treatable malignant diseases--including heart failure--are entitled to specialist care. CMAJ (2005) 0.87
Micronutrients and their supplementation in chronic cardiac failure. An update beyond theoretical perspectives. Heart Fail Rev (2006) 0.84
Heart failure management--a broader view required. Eur Heart J (1998) 0.78
Posttraumatic stress and depression: potential pathways to disease burden among heart failure patients. Anxiety Stress Coping (2015) 0.77
Contemporary management of heart failure in clinical practice. Heart (2002) 0.77
Metabolic manipulation in chronic heart failure: study protocol for a randomised controlled trial. Trials (2011) 0.77
Carvedilol in the treatment of elderly patients with chronic heart failure. Clin Interv Aging (2008) 0.77
Right ventricular dysfunction as predictor of longer hospital stay in patients with acute decompensated heart failure: a prospective study in Indonesian population. Cardiovasc Ultrasound (2016) 0.75
Taking heart failure seriously. BMJ (2000) 0.75
Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? Eur Heart J (2000) 4.99
Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation (1999) 3.06
Captopril in heart failure. A double blind controlled trial. Br Heart J (1984) 2.85
Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state. Br Heart J (1985) 2.74
GISSI-3. Lancet (1994) 2.53
Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation (2000) 2.49
Unsuspected renal artery stenosis in peripheral vascular disease. BMJ (1990) 2.42
Enhanced basal nitric oxide production in heart failure: another failed counter-regulatory vasodilator mechanism? Lancet (1994) 2.25
Severe hypotension after first dose of enalapril in heart failure. Br Med J (Clin Res Ed) (1985) 2.14
Flosequinan: a new vasodilator for the treatment of heart failure. Br J Hosp Med (1993) 2.03
Reliability and validity of survey data on sexual behaviour. Health Transit Rev (1994) 2.02
The evidence for beta blockers in heart failure. BMJ (1999) 1.84
The heart failure epidemic: exactly how big is it? Eur Heart J (2001) 1.73
Effects of increased inspired oxygen concentrations on exercise performance in chronic heart failure. Lancet (1992) 1.65
Natural history of secundum atrial septal defect in adults after medical or surgical treatment: a historical prospective study. Br Heart J (1994) 1.59
Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J (2000) 1.55
Endothelin B receptors are functionally important in mediating vasoconstriction in the systemic circulation in patients with left ventricular systolic dysfunction. J Am Coll Cardiol (1999) 1.47
Genetic testing for familial hypertrophic cardiomyopathy in newborn infants. BMJ (1995) 1.44
Plasma alpha natriuretic peptide in cardiac impairment. Br Med J (Clin Res Ed) (1986) 1.44
Risk stratification in chronic heart failure. Eur Heart J (1998) 1.33
Is the prognosis of heart failure improving? J Am Coll Cardiol (2000) 1.29
Reduced alveolar-capillary membrane diffusing capacity in chronic heart failure. Its pathophysiological relevance and relationship to exercise performance. Circulation (1995) 1.27
Should we screen for asymptomatic left ventricular dysfunction to prevent heart failure? Eur Heart J (1998) 1.23
What is the ideal study design for evaluation of treatment for heart failure? Insights from trials assessing the effect of ACE inhibitors on exercise capacity. Eur Heart J (1996) 1.23
Relation of arrhythmias and electrolyte abnormalities to survival in patients with severe chronic heart failure. Circulation (1987) 1.12
Clinical events leading to the progression of heart failure: insights from a national database of hospital discharges. Eur Heart J (2001) 1.09
Reproductive health needs of young persons in markets and motor parks in south west Nigeria. Afr J Med Med Sci (2001) 1.08
Chronic heart failure and micronutrients. J Am Coll Cardiol (2001) 1.07
Clinical trials update: IMPROVEMENT-HF, COPERNICUS, MUSTIC, ASPECT-II, APRICOT and HEART. Eur J Heart Fail (2000) 1.07
Cardiovascular effects of training for a marathon run in unfit middle aged men. Br Med J (Clin Res Ed) (1987) 1.06
Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. Am Heart J (1994) 1.01
Etiology and response to drug treatment in heart failure. J Am Coll Cardiol (1998) 1.00
The link between postnatal abstinence and extramarital sex in Côte d'Ivoire. Stud Fam Plann (2001) 0.97
Mode of death in chronic heart failure. A request and proposition for more accurate classification. Eur Heart J (1996) 0.97
Clinical, haemodynamic, and antiarrhythmic effects of long term treatment with amiodarone of patients in heart failure. Br Heart J (1987) 0.97
Placebo controlled trial of xamoterol versus digoxin in chronic atrial fibrillation. Br Heart J (1990) 0.97
ACE inhibitors in heart failure. What dose? Postgrad Med J (1995) 0.96
Increased alveolar/capillary membrane resistance to gas transfer in patients with chronic heart failure. Br Heart J (1994) 0.94
Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival. Arch Intern Med (2001) 0.94
Acute saline infusion reduces alveolar-capillary membrane conductance and increases airflow obstruction in patients with left ventricular dysfunction. Circulation (1999) 0.94
Short-term haemodynamic effects of BQ-123, a selective endothelin ET(A)-receptor antagonist, in chronic heart failure. Lancet (1998) 0.93
Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology--WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME. Eur J Heart Fail (2001) 0.91
Systematic review of the management of atrial fibrillation in patients with heart failure. Eur Heart J (2000) 0.91
Sudden death in heart failure: vascular or electrical? Eur J Heart Fail (1999) 0.91
Angiotensin converting enzyme inhibition in heart failure. Br J Clin Pharmacol (1984) 0.90
The Effect of birth spacing on childhood mortality in Pakistan. Popul Stud (Camb) (1984) 0.90
Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-centre Dose-ranging Study Investigators. Lancet (1998) 0.90
ACE inhibitors and heart failure. Lancet (1992) 0.90
The use of captopril in the management of cardiac failure. Scott Med J (1984) 0.89
Impaired pulmonary diffusion during exercise in patients with chronic heart failure. Circulation (1999) 0.88
The renal effects of dopamine and dobutamine in stable chronic heart failure. Postgrad Med J (1992) 0.87
Are beta-blockers effective in patients who develop heart failure soon after myocardial infarction? A meta-regression analysis of randomised trials. Eur J Heart Fail (2000) 0.87
Captopril in heart failure: a double-blind study of the effects on renal function. J Cardiovasc Pharmacol (1986) 0.85
Angiography and the aetiology of heart failure. Postgrad Med J (1995) 0.85
The standard electrocardiogram as a screening test for hypertrophic cardiomyopathy. Am J Cardiol (1995) 0.85
Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio.net Editorial Team. Eur J Heart Fail (1999) 0.84
The effects of captopril on serum digoxin and urinary urea and digoxin clearances in patients with congestive heart failure. Am Heart J (1986) 0.84
Influence of angiotensin converting enzyme inhibition on exercise performance and clinical symptoms in chronic heart failure: a multicentre, double-blind, placebo-controlled trial. Eur Heart J (1993) 0.84
The control of adrenergic function in heart failure: therapeutic intervention. Heart Fail Rev (2000) 0.83
Heart failure, renal function, and angiotensin converting enzyme inhibitors. Kidney Int Suppl (1987) 0.83
Plasma atrial natriuretic peptide concentrations during exercise in sodium replete and deplete normal man. Clin Sci (Lond) (1987) 0.83
Heart failure update. Eur J Heart Fail (1999) 0.82
Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. Eur J Heart Fail (2001) 0.82
Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT. Eur J Heart Fail (2000) 0.82
Co-expression of renin-angiotensin system component genes in human atrial tissue. J Hypertens Suppl (1994) 0.82
Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. The Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial Investigators. J Card Fail (1998) 0.82
Elevated plasma endothelin concentrations in heart failure; an effect of angiotensin II? Eur Heart J (1994) 0.82
Total body and serum electrolyte composition in heart failure: the effects of captopril. Eur Heart J (1985) 0.82
Clinical trials update: Highlights of the Scientific Sessions of Heart Failure 2001, a meeting of the Working Group on Heart Failure of the European Society of Cardiology. CONTAK-CD, CHRISTMAS, OPTIME-CHF. Eur J Heart Fail (2001) 0.81
Bronchial hyperresponsiveness in heart failure. N Engl J Med (1993) 0.80
Effect of intense angiotensin II suppression on the diuretic response to furosemide during chronic ACE inhibition. Circulation (1994) 0.79
Effect of supine posture on respiratory mechanics in chronic left ventricular failure. Am J Respir Crit Care Med (2000) 0.79
Endothelin antagonists for chronic heart failure: do they have a role? Eur Heart J (2001) 0.79
Cardioreparation and the concept of modulating cardiovascular structure and function. Blood Press (1993) 0.79
Cardiovascular responses to verapamil and propranolol in hypertensive patients. J Hypertens Suppl (1985) 0.79
Plasma atrial natriuretic peptide: responses to modest and severe sodium restriction. J Hypertens Suppl (1986) 0.79
The carvedilol hibernation reversible ischaemia trial; marker of success (CHRISTMAS). The CHRISTMAS Study Steering Committee and Investigators. Eur J Heart Fail (1999) 0.78
Endothelin-1 has haemodynamic effects at pathophysiological concentrations in patients with left ventricular dysfunction. Cardiovasc Res (1998) 0.78
Depression and heart failure--not yet a target for therapy? Eur Heart J (1999) 0.77
Renal response to candoxatrilat in patients with heart failure. J Am Coll Cardiol (1995) 0.77
Area variations in use of modern contraception in rural Bangladesh: a multilevel analysis. J Biosoc Sci (1999) 0.77
The carvedilol hibernation reversible ischaemia trial, marker of success (CHRISTMAS) study. Methodology of a randomised, placebo controlled, multicentre study of carvedilol in hibernation and heart failure. Int J Cardiol (2000) 0.77
Aspirin, myocardial infarction, and gastrointestinal bleeding. Lancet (1999) 0.77
Management strategies in unstable coronary artery disease--current problems and future directions. The UCAD Council. Clin Cardiol (1999) 0.77
Validation of an echocardiographic wall motion index in heart failure due to ischaemic heart disease. Eur J Heart Fail (2001) 0.77
Structural and functional assessment of small arteries in patients with chronic heart failure. Clin Sci (Lond) (1999) 0.77
Management strategies for a better outcome in unstable coronary artery disease. Clin Cardiol (1998) 0.76
Plasma neuro-endocrine activity in very elderly subjects and patients with and without heart failure. Eur Heart J (1995) 0.76
Effects of aging on neuroendocrine activation in subjects and patients in the presence and absence of heart failure with left ventricular systolic dysfunction. Am J Cardiol (1996) 0.76
Non-invasive evaluation of cardiac function in young patients with type 1 diabetes. Diabet Med (1989) 0.76
Torsade de pointes: chaos, sixteen years on? Br Heart J (1992) 0.76
Amiodarone after myocardial infarction: EMIAT and CAMIAT trials. Lancet (1997) 0.75
Is aspirin safe in heart failure? more data. Heart (1996) 0.75
Coronary angioplasty: is cardiological practice in the U.S.A. really the gold standard for Europe? Eur Heart J (1993) 0.75
Are all beta-blockers for heart failure the same? Circulation (2000) 0.75
Adverse event with first-dose perindopril in congestive heart failure. Lancet (1997) 0.75
Natriuretic peptides in patients with atrial fibrillation and advanced chronic heart failure: determinants and prognostic value of (NT-)ANP and (NT-pro) BNP. Europace (2007) 0.75
Survival trends, coronary event rates, and the MONICA project. Monitoring trends and determinants in cardiovascular disease. Lancet (1999) 0.75
The genetics of hypertrophic cardiomyopathy. Br Heart J (1991) 0.75
Interpretation of Thrombosis Prevention Trial. Lancet (1998) 0.75